Hematopoiesis News

Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.

Comparison of Autologous and Allogeneic Hematopoietic Cell Transplantation Strategies in Patients with Primary Plasma Cell Leukemia, with Dynamic Prediction Modeling

June 30, 2022

[Haematologica] Researchers undertook a retrospective analysis from 1998-2014 of 751 patients with primary plasma cell leukaemi undergoing one of four transplant strategies; single autologous transplant, single allogeneic transplant or a combined tandem transplant either auto-allo or auto-auto.

Combination Elotuzumab and Lenalidomide Treatment Efficacy Is Dependent on Crosstalk between NK Cells, Monocytes and Myeloma Cells

June 30, 2022

[Haematologica] Researchers used a humanized myeloma mouse model and adoptive transfer of human NK cells to show that elotuzumab and lenalidomide treatment controlled myeloma growth, and this was mediated through CD16 on NK cells.

STAT1 Is Essential for HSC Function and Maintains MHCIIhi Stem Cells that Resists Myeloablation and Neoplastic Expansion

June 30, 2022

[Blood] The authors showed that loss of STAT1 altered the steady state hematopoietic stem/progenitor cell landscape, impaired HSC function in transplantation assays, delayed blood cell regeneration following myeloablation, and disrupted molecular programs which protect HSCs including control of quiescence.

Epigenetic Modifier SMCHD1 Maintains a Normal Pool of Long-Term Hematopoietic Stem Cells

June 30, 2022

[iScience] Structural maintenance of chromosomes hinge domain containing 1 (Smchd1)-deleted mice maintained steady-state hematopoiesis despite showing impaired reconstitution capacity in competitive bone marrow transplantations and age-related hematopoietic stem cell loss.

Clonal Reconstruction from Co-Occurrence of Vector Integration Sites Accurately Quantifies Expanding Clones In Vivo

June 28, 2022

[Nature Communications] Tracing of integration sites (IS) leads to mis-quantification of the true clonal spectrum and limits safety considerations in gene therapies. Hence, scientists used correlations between repeated measurements of IS abundances to estimate their mutual similarity and identify clusters of co-occurring IS, for which they assume a clonal origin.

Lentivector Cryptic Splicing Mediates Increase in CD34+ Clones Expressing Truncated HMGA2 in Human X-Linked Severe Combined Immunodeficiency

June 28, 2022

[Nature Communications] Researchers report vector insertion site (VIS) analysis in blood lineages from first eight treated patients with longer follow up found a > 60-fold increase in frequency of forward-orientated VIS within intron 3 of the High Mobility Group AT-hook 2 gene.

Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma

June 28, 2022

[Blood Reviews] Investigators review the basic biology and known health effects of clonal hematopoiesis (CH), and focus on the clinical relevance of CH in lymphoma and multiple myeloma.

Toward the Dissection of Hematopoietic Stem Cell Fates and Their Determinants

June 28, 2022

[Current Opinion in Genetics & Development] Recently, genetic in vivo approaches have been developed for lineage tracing of differentiating progeny emerging from hematopoietic stem cell (HSC) over time (output), and for high-resolution, endogenous barcoding to uncover the lineages that HSC contribute to (fate).

Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

June 28, 2022

[Precision BioSciences, Inc.] Precision BioSciences, Inc. announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG.

Veloxis Pharmaceuticals Announces Dosing of the First Patient by Partner Xenikos in the Global Phase III Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute...

June 28, 2022

[Veloxis Pharmaceuticals] Veloxis Pharmaceuticals announced dosing of the first patient by its partner, Xenikos, in a Phase III clinical study designed to evaluate T-Guard® versus ruxolitinib for the treatment of patients with Grade III or IV SR-aGVHD following allogeneic hematopoietic stem cell transplant.

Long-Term Hematopoietic Stem Cells as a Parasite Niche during Treatment Failure in Visceral Leishmaniasis

June 27, 2022

[Communications Biology] Double bioluminescent/fluorescent Leishmania infantum and L. donovani reporter lines enabled the identification of long-term hematopoietic stem cells as a niche in the bone marrow with remarkably high parasite burdens, a feature confirmed for human hematopoietic stem cells.

Kinetics of Disappearance and Appearance of Isoagglutinins A and B after ABO-Incompatible Hematopoietic Stem Cell Transplantation

June 27, 2022

[Bone Marrow Transplantation] In a one-year follow-up, data of 136 ABO-incompatible hematopoietic stem cell allogeneic transplanted patients were studied, of which 60 had major, 61 minor and 15 bidirectional incompatibility.

Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.